Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zimberelimab, Domvanalimab, and Etrumadenant in Previously Treated Non-Small Cell Lung Cancer
NCT04791839Phase 2Active, not recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Aug 2021
- Primary completion
- Oct 2026
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of zimberelimab, domvanalimab and etrumadenant in non-small cell lung cancer (NSCLC) (2 cohorts), sponsored by Washington University School of Medicine. Primary endpoint: Objective Response Rate at 9 months. Started Aug 2021; status: active, not recruiting.
02
Drugs
zimberelimabdomvanalimabetrumadenant
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04791839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04791839.